Medpace (MEDP) & Sorrento Therapeutics (SRNE) Critical Contrast

Sorrento Therapeutics (NASDAQ: SRNE) and Medpace (NASDAQ:MEDP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Earnings & Valuation

How to Become a New Pot Stock Millionaire

This table compares Sorrento Therapeutics and Medpace’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sorrento Therapeutics $151.85 million 3.24 $9.13 million ($1.14) -4.74
Medpace $436.15 million 2.94 $39.12 million $1.52 23.80

Medpace has higher revenue and earnings than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sorrento Therapeutics and Medpace’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sorrento Therapeutics 29.72% 38.43% 11.15%
Medpace 8.97% 10.55% 6.29%

Institutional and Insider Ownership

11.6% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 23.6% of Medpace shares are owned by institutional investors. 5.0% of Sorrento Therapeutics shares are owned by insiders. Comparatively, 25.8% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Sorrento Therapeutics has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Comparatively, Medpace has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Sorrento Therapeutics and Medpace, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sorrento Therapeutics 0 0 5 0 3.00
Medpace 0 6 1 0 2.14

Sorrento Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 214.81%. Medpace has a consensus price target of $36.75, indicating a potential upside of 1.58%. Given Sorrento Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Sorrento Therapeutics is more favorable than Medpace.

Summary

Sorrento Therapeutics beats Medpace on 8 of the 14 factors compared between the two stocks.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

About Medpace

Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.

Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Traders Sell Shares of iShares China Large-Cap ETF  on Strength
Traders Sell Shares of iShares China Large-Cap ETF on Strength
Traders Sell Comcast  on Strength Following Insider Selling
Traders Sell Comcast on Strength Following Insider Selling
Dogecoin  24 Hour Volume Hits $27.04 Million
Dogecoin 24 Hour Volume Hits $27.04 Million
Ormeus Coin  Trading Down 22.4% Over Last 7 Days
Ormeus Coin Trading Down 22.4% Over Last 7 Days
COMSA [ETH] Tops 24 Hour Trading Volume of $185,973.00
COMSA [ETH] Tops 24 Hour Trading Volume of $185,973.00
Zacks: Analysts Anticipate Oracle Co.  Will Post Earnings of $0.94 Per Share
Zacks: Analysts Anticipate Oracle Co. Will Post Earnings of $0.94 Per Share


Leave a Reply

© 2006-2018 Ticker Report. Google+.